Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R F Schlenk

Showing results (31-40 of 40) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 40 results.
ESMO Open|July 8, 2025
CDK4/6 inhibition in advanced chordoma: final results of the NCT PMO-1601 trialM-V Teleanu, C E Heilig, S Pirmann, et al.
Leukemia|November 25, 2016
Acute myeloid leukemia derived from lympho-myeloid clonal hematopoiesisF Thol, S Klesse, L Köhler, et al.
Leukemia|February 8, 2019
Randomized phase-II trial evaluating induction therapy with idarubicin and etoposide plus sequential or concurrent azacitidine and maintenance therapy with azacitidineR F Schlenk, D Weber, W Herr, et al.
Blood Cancer Journal|May 27, 2017
Condensed versus standard schedule of high-dose cytarabine consolidation therapy with pegfilgrastim growth factor support in acute myeloid leukemiaS Jaramillo, A Benner, J Krauter, et al.
Annals of Hematology|November 2, 2017
Epidemiological, genetic, and clinical characterization by age of newly diagnosed acute myeloid leukemia based on an academic population-based registry study (AMLSG BiO)Gabriele Nagel, D Weber, E Fromm, et al.
ESMO Open|November 22, 2021
Rationale and design of the CRAFT (Continuous ReAssessment with Flexible ExTension in Rare Malignancies) multicenter phase II trialC E Heilig, P Horak, S Kreutzfeldt, et al.
Leukemia|March 22, 2017
Characteristics and outcome of patients with therapy-related acute promyelocytic leukemia front-line treated with or without arsenic trioxideS Kayser, J Krzykalla, M A Elliott, et al.
ESMO Gastrointestinal Oncology|February 6, 2026
17.6% of patients in a German cohort with exocrine pancreatic cancer were diagnosed with a genetic tumor syndrome-a case for universal genetic testing?D William, M Bermúdez, A Kübler, et al.
Leukemia|June 30, 2020
Therapy-related myelodysplastic syndromes deserve specific diagnostic sub-classification and risk-stratification-an approach to classification of patients with t-MDSA Kuendgen, M Nomdedeu, H Tuechler, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 21, 2022
Comprehensive cancer predisposition testing within the prospective MASTER trial identifies hereditary cancer patients and supports treatment decisions for rare cancersA Jahn, A Rump, T J Widmann, et al.
Pageof 4

Showing results (31-40 of 40) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 40 results.
ESMO Open|July 8, 2025
CDK4/6 inhibition in advanced chordoma: final results of the NCT PMO-1601 trialM-V Teleanu, C E Heilig, S Pirmann, et al.
Leukemia|November 25, 2016
Acute myeloid leukemia derived from lympho-myeloid clonal hematopoiesisF Thol, S Klesse, L Köhler, et al.
Leukemia|February 8, 2019
Randomized phase-II trial evaluating induction therapy with idarubicin and etoposide plus sequential or concurrent azacitidine and maintenance therapy with azacitidineR F Schlenk, D Weber, W Herr, et al.
Blood Cancer Journal|May 27, 2017
Condensed versus standard schedule of high-dose cytarabine consolidation therapy with pegfilgrastim growth factor support in acute myeloid leukemiaS Jaramillo, A Benner, J Krauter, et al.
Annals of Hematology|November 2, 2017
Epidemiological, genetic, and clinical characterization by age of newly diagnosed acute myeloid leukemia based on an academic population-based registry study (AMLSG BiO)Gabriele Nagel, D Weber, E Fromm, et al.
ESMO Open|November 22, 2021
Rationale and design of the CRAFT (Continuous ReAssessment with Flexible ExTension in Rare Malignancies) multicenter phase II trialC E Heilig, P Horak, S Kreutzfeldt, et al.
Leukemia|March 22, 2017
Characteristics and outcome of patients with therapy-related acute promyelocytic leukemia front-line treated with or without arsenic trioxideS Kayser, J Krzykalla, M A Elliott, et al.
ESMO Gastrointestinal Oncology|February 6, 2026
17.6% of patients in a German cohort with exocrine pancreatic cancer were diagnosed with a genetic tumor syndrome-a case for universal genetic testing?D William, M Bermúdez, A Kübler, et al.
Leukemia|June 30, 2020
Therapy-related myelodysplastic syndromes deserve specific diagnostic sub-classification and risk-stratification-an approach to classification of patients with t-MDSA Kuendgen, M Nomdedeu, H Tuechler, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 21, 2022
Comprehensive cancer predisposition testing within the prospective MASTER trial identifies hereditary cancer patients and supports treatment decisions for rare cancersA Jahn, A Rump, T J Widmann, et al.
Pageof 4